Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing and lunch

172P - Early impact of a personalised cancer interception programme for women at non-genetic high risk of breast cancer (BC)

Date

12 May 2023

Session

Poster viewing and lunch

Presenters

Lucie Veron

Citation

Annals of Oncology (2023) 8 (1suppl_4): 101222-101222. 10.1016/esmoop/esmoop101222

Authors

L. Veron1, M. Aupomerol1, K. Ouali1, T. Pudlarz1, L. Degousée1, P. Abdayem1, H. Caron1, B. Raynard1, G. Hesry1, O. Caron2, S. Delaloge3

Author affiliations

  • 1 Gustave Roussy - Cancer Campus, Villejuif/FR
  • 2 Gustave Roussy, Villejuif/FR
  • 3 Institut Gustave Roussy, Villejuif/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 172P

Background

Risk-based cancer prevention is a major future strategy. “Interception” is a French pilot, mixed community-hospital and digital-physical programme based on 4 pillars: 1. community-based identification of people at high risk of cancer; 2. a One-Stop Shop (OSS) including individual visits and group workshops to inform and empower patients and design their shared personalised prevention plan; 3. Implementation of this plan in community practice; 4. Fast cancer care pathway if required. We assessed the pathway dedicated to women at increased non-genetic risk of BC (CANRISK-based 5-year risk of invasive BC >2.5%).

Methods

We analysed data of women at high risk of BC non linked to a germline variant seen between 02/2021 and 12/2022. Nutritional habits and physical activity assessments used the WCRF score. Perception of knowledge on risk, prevention and screening, and self-evaluated lifetime probability and compared probability of BC, were assessed before and 8 days after OSS (analogue visual scales); comparisons used paired Wilcoxon tests.

Results

141 women at high non-genetic BC risk entered the programme. Mean age was 40.5 years [32.2-49], 81% had tertiary education. Recommended BC screening scheme was modified in 64% (increased mammography frequency: 36 (50%), addition of yearly MRI: 36 (50%)). Identified BC prevention targets were: insufficient physical activity (83%), overweight or obesity (36%), alcohol consumption (57% incl. 5% with >1 alcohol drink/day), current smoking (21%). 97% had at least 1 prevention target. The mean perceived knowledge on BC risk improved (58.0% before vs 87.4% after, p<0.05). Self-evaluated risk of BC dropped significantly after OSS (Perceived lifetime risk 70% (σ=17.1) before vs 35% (σ=22.5) after, p<0.05). Compared perceived probability of BC remained unchanged. 98% of women were highly or very highly satisfied with the programme.

Conclusions

A programme dedicated to women at high BC risk has the ability to improve screening measures in conformity with current guidelines (51%), identify relevant prevention targets (97%), improve knowledge on one’s individual situation by 50%, and improve perceived cancer risk’s accuracy.

Legal entity responsible for the study

Gustave Roussy Institute.

Funding

Odyssea (Charity).

Disclosure

L. Veron, S. Delaloge: Financial Interests, Institutional, Sponsor/Funding, Charity: Odyssea. G. Hesry: Financial Interests, Institutional, Full or part-time Employment: Odyssea. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.